1. Home
  2. TBPH vs HZO Comparison

TBPH vs HZO Comparison

Compare TBPH & HZO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • HZO
  • Stock Information
  • Founded
  • TBPH 2013
  • HZO 1998
  • Country
  • TBPH United States
  • HZO United States
  • Employees
  • TBPH N/A
  • HZO N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • HZO Auto & Home Supply Stores
  • Sector
  • TBPH Health Care
  • HZO Consumer Discretionary
  • Exchange
  • TBPH Nasdaq
  • HZO Nasdaq
  • Market Cap
  • TBPH 699.0M
  • HZO 604.0M
  • IPO Year
  • TBPH N/A
  • HZO 1998
  • Fundamental
  • Price
  • TBPH $18.81
  • HZO $24.65
  • Analyst Decision
  • TBPH Strong Buy
  • HZO Strong Buy
  • Analyst Count
  • TBPH 4
  • HZO 4
  • Target Price
  • TBPH $24.25
  • HZO $34.00
  • AVG Volume (30 Days)
  • TBPH 569.5K
  • HZO 401.2K
  • Earning Date
  • TBPH 11-10-2025
  • HZO 11-13-2025
  • Dividend Yield
  • TBPH N/A
  • HZO N/A
  • EPS Growth
  • TBPH N/A
  • HZO N/A
  • EPS
  • TBPH 0.58
  • HZO N/A
  • Revenue
  • TBPH $80,327,000.00
  • HZO $2,309,288,000.00
  • Revenue This Year
  • TBPH $79.82
  • HZO $4.01
  • Revenue Next Year
  • TBPH N/A
  • HZO $4.20
  • P/E Ratio
  • TBPH $32.54
  • HZO N/A
  • Revenue Growth
  • TBPH 27.12
  • HZO N/A
  • 52 Week Low
  • TBPH $7.90
  • HZO $16.85
  • 52 Week High
  • TBPH $18.96
  • HZO $35.46
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 68.84
  • HZO 54.66
  • Support Level
  • TBPH $17.50
  • HZO $21.42
  • Resistance Level
  • TBPH $18.58
  • HZO $23.10
  • Average True Range (ATR)
  • TBPH 0.99
  • HZO 1.42
  • MACD
  • TBPH 0.16
  • HZO 0.16
  • Stochastic Oscillator
  • TBPH 98.49
  • HZO 85.29

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About HZO MarineMax Inc. (FL)

MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S.

Share on Social Networks: